Regenecyte is under clinical development by StemCyte and currently in Phase I for Stroke. According to GlobalData, Phase I drugs for Stroke have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Regenecyte’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Regenecyte overview

Regenecyte is under development for the treatment of hematopoietic system diseases, unspecified immunological disorders, unspecified metabolic disorders, acute stroke, cerebral palsy and post-COVID syndrome. The therapeutic candidate comprises of allogeneic human umbilical cord blood hematopoietic stem cells,  administered through parenteral route.

StemCyte overview

StemCyte is a cord blood therapeutic company offers public and private cord blood banking services. The company collects, transports, processes, freezes, and stores stem cells. It offers insulated collection kit, sterile collection, transportation, plasma depletion, red cell reduction, and testing services. StemCyte’s cord blood stem cells are used in the treatment of leukemia, multiple myeloma, lymphomas, thalassemias, fanconi anemia, sickle cell anemia, and immune deficiency diseases, autoimmune disease, lupus, and inheritable diseases. It helps customers to store their cord blood for their own use and to donate their cord blood. The company caters to hospitals and transplant centers. It has operations in the US, India and Taiwan. StemCyte is headquartered in Baldwin Park, California, the US.

For a complete picture of Regenecyte’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.